simeprevir sodium · Janssen Prods · NDA 205123
Olysio
Earliest generic entry, as listed
5 Sep 2029
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 8148399.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8148399 | substance, product, use U-1467 | 5 Sep 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 205123 · 001 · RLD · discontinued | capsule, oral | EQ 150MG BASE | 5 Sep 2029 |
Expired or delisted (7)
- US 8349869 · substance, product, use U-1467 · 28 Jul 2026
- US 8741926 · substance, use U-1467 · 28 Jul 2026
- US 8754106 · substance, use U-1467 · 28 Jul 2026
- US 9040562 · substance, product, use U-1467 · 28 Jul 2026
- US 9353103 · use U-1467 · 28 Jul 2026
- US 9623022 · use U-1467 · 28 Jul 2026
- US 9856265 · substance, product, use U-1467 · 28 Jul 2026